A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03559270

Recruitment Status : Enrolling by invitation

First Posted : June 18, 2018

Last Update Posted : November 22, 2019

Sponsor:

Collaborator:

Incyte Corporation

Information provided by (Responsible Party):

Eli Lilly and Company

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Enrolling by invitation
Estimated Primary Completion Date :	November 25, 2021
Estimated Study Completion Date :	December 27, 2021

To Top